Open AccessA Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age
Author(s) -
Byung Wook Eun,
Taek Jin Lee,
Jina Lee,
Ki Hwan Kim,
Dong Ho Kim,
Dae Sun Jo,
Sun Hee Shin,
Hun Kim,
Kyung Ho Kim,
Yun Kyung Kim
Publication year - 2019
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000002406
Subject(s) - immunogenicity , medicine , live attenuated influenza vaccine , influenza vaccine , trivalent influenza vaccine , virology , hemagglutination assay , titer , adverse effect , immunology , vaccination , antibody
Cell culture-derived influenza vaccines have several important advantages over egg-based influenza vaccines. The quadrivalent influenza vaccine may offer broader protection against seasonal influenza than trivalent influenza vaccine by containing 1 more B strain. The purpose of this study was to evaluate the immunogenicity and safety of NBP607-QIV, a novel cell culture-derived inactivated quadrivalent influenza vaccine (cIIV4), in children and adolescents.